enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
종목 코드 NVNO
회사 이름enVVeno Medical Corp
상장일May 31, 2018
CEOMr. Robert A. Berman
직원 수37
유형Ordinary Share
회계 연도 종료May 31
주소70 Doppler
도시IRVINE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92618
전화19492612900
웹사이트https://envveno.com/
종목 코드 NVNO
상장일May 31, 2018
CEOMr. Robert A. Berman
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음